bioRxiv Science⌕ Search

Biology subjects

Chau, F.

Publications and source records attributed to Chau, F..

5 recordsLinked to original sources

Identification of specific metabolic capacities associated with major extraintestinal pathogenic Escherichia coli lineages

Bacterial niche colonization relies on multiple factors, among which the metabolic capacity to utilize specific substrates is pivotal, especially within complex microbiota where nutrient competition is intense. Escherichia coli, a gut commensal of humans and vertebrates, is also an opportunistic pathogen responsible for both intestinal and extraintestinal infections, including bloodstream infections (BSI). To identify metabolic specificities of pathogenic strains that could explain the emergence and success of major clones, we leveraged a well-characterized dataset of 1,498 genomes from both commensal and extraintestinal pathogenic epidemiologically relevant French isolates. Using a pangenomic framework, we conducted a large-scale analysis of metabolic pathways. Although metabolism was far more conserved than gene content, we found substantial metabolic diversity across the species, with over 50% of pathways being variable, mainly involving biosynthetic and degradation processes. Phylogeny had a major impact on metabolic profiles, while no specific pathway was associated with lifestyle (commensal vs. pathogenic) or BSI portal of entry. However, we identified clone-specific metabolic capacities. For example, pathways involved in 5-deoxynucleoside recycling were enriched in the major extraintestinal pathogen (ExPEC) clone STc69. In phylogroup B2, several clone-specific pathways enabled degradation of plant-derived compounds. Notably, detailed analysis of the D-apiose degradation revealed a functional pathway strongly associated with the STc131 and STc14 pandemic clones. Overall, our study highlights multiple lineage-specific metabolic capacities that may contribute to the ecological success and dissemination of most prevalent ExPEC clones. ImportanceAccording to the nutrient-niche hypothesis, both commensal and pathogenic E. coli strains must exploit distinct substrates to grow and persist in their primary habitat alongside resident microbiota. Such niche differentiation also occurs between E. coli populations competing within the same environment and partly explains the stable coexistence of strains in the gut. With this in mind, we search for specific associations between metabolic pathways and strain origin. However, metabolic profiles were predominantly shaped by phylogeny, reflecting the species clonal structure and the close link between phylogenetic background and lifestyle. Among the lineage-specific determinants, we identified several pathways associated with worldwide spread clones responsible for bloodstream infections, supporting the existence of clone-specific strategies for niche adaptation.

genomics↗

Impact of the inoculum size on the in vivo activity of the aztreonam-avibactam combination in a murine model of peritonitis due to Escherichia coli expressing CTX-M-15 and NDM-1

BackgroundThe combination of aztreonam (ATM) and avibactam (AVI) is an attractive option to treat infections caused by extended spectrum {beta}-lactamase plus NDM-1-producing Enterobacteriaceae. Since ATM activity was shown to be severely impacted by an increase in the inoculum size in vitro, we wondered whether ATM-AVI activity could be impaired in high-inoculum infections. MethodsWe analyzed the impact of the inoculum size on ATM-AVI activity in vitro and in a murine model of peritonitis due to susceptible E. coli CFT073-pTOPO and its isogenic derivatives producing NDM-1 (E. coli CFT073-NDM1) and CTX-M-15 plus NDM-1 (E. coli CFT073-CTXM15-NDM1). The impact of the inoculum size on bacterial morphology was studied by microscopic examination. ResultsIn vitro, at standard (105) inoculum, E. coli CFT073-CTXM15-NDM1 was resistant to ATM but susceptible to the ATM-AVI combination. At high (107) inoculum, MICs of ATM alone and of the ATM-AVI combination reached > 512 and 64 mg/L respectively, against all tested strains. ATM led to bacterial filamentation when active against the bacteria, i.e., in monotherapy or in combination with AVI against susceptible E. coli CFT073-pTOPO, and only in combination with AVI against E. coli CFT073-CTXM15-NDM1. In vivo, increase in the inoculum led to a drastic decrease in the activity of ATM alone against E. coli CFT073-pTOPO, and of ATM-AVI against E. coli CFT073-CTXM15-NDM1. ConclusionOur results suggest a high in vivo impact of the inoculum increase on the activity of ATM alone against ATM-susceptible E. coli, and of ATM-AVI against CTX-M-15 plus NDM-1 producing E. coli. Clinicians must be aware of the risk of failures when using AZT-AVI in high inoculum infections.

microbiology↗

Faecal carriage of ESBL-producing Escherichia coli in a remote region of Niger

ObjectiveWhole genome sequencing (WGS) of extended-spectrum {beta}-lactamase-producing Escherichia coli (ESBL-E. coli) in developing countries is lacking. Here we describe the population structure and molecular characteristics of ESBL-E. coli faecal isolates in rural Southern Niger. MethodsStools of 383 healthy participants were collected among which 92.4% were ESBL-E. coli carriers; 90 of these ESBL-E. coli containing stools (109 ESBL-E. coli isolates) were further analysed by WGS, using short- and long-reads. ResultsMost isolates belonged to the commensalism-adapted phylogroup A (83.5%), with high clonal diversity. The blaCTX-M-15 gene was the major ESBL determinant (98.1%), chromosome-integrated in approximately 50% of cases, in multiple integration sites. When plasmid-borne, blaCTX-M-15 was found in IncF (57.4%) and IncY plasmids (26.2%). Closely related plasmids were found in different genetic backgrounds. Genomic environment analysis of blaCTX-M-15 in closely related strains argued for mobilisation between plasmids or from plasmid to chromosome. ConclusionsMassive prevalence of community faecal carriage of CTX-M-15-producing E. coli was observed in a rural region of Niger due to the spread of highly diverse A phylogroup commensalism-adapted clones, with frequent chromosomal integration of blaCTX-M-15. Plasmid spread was also observed. These data suggest a risk of sustainable implementation of ESBL in community faecal carriage.

microbiology↗

Chlorhexidine reduced susceptibility associated to tetracycline resistance in clinical isolates of Escherichia coli

Chlorhexidine is a widely used antiseptic in hospital and community healthcare. Decreased susceptibility to this compound has been recently described in Klebsiella pneumoniae and Pseudomonas aeruginosa, together with cross-resistance to colistin. Surprisingly, few data are available for Escherichia coli, the main species responsible for community and healthcare-associated infections. In order to decipher chlorhexidine resistance mechanisms in E. coli, we studied both in vitro derived and clinical isolates through whole-genome sequence analysis. Comparison of strains grown in vitro under chlorhexidine pressure identified mutations in the gene mlaA coding for a phospholipid transport system. Phenotypic analyses of single-gene mutant from the Keio collection confirmed the role of this mutation in the decreased susceptibility to chlorhexidine. However, mutations in mlaA were not found in isolates from large clinical collections. In contrast, genome wide association studies (GWAS) showed that, in clinical strains, chlorhexidine reduced susceptibility was associated with the presence of tetA genes of class B coding for efflux pumps and located in a Tn10 transposon. Construction of recombinant strains in E. coli K-12 confirmed the role of tetA determinant in acquired resistance to both chlorhexidine and tetracycline. Our results reveal two different evolutionary paths leading to chlorhexidine decreased susceptibility: one restricted to in vitro evolution conditions and involving a retrograde phospholipid transport system; the other observed in clinical isolates associated with efflux pump TetA. None of these mechanisms provides cross-resistance to colistin or to the cationic surfactant octenidine. This work demonstrates the GWAS power to identify new resistance mechanisms in bacterial species.

microbiology↗

Unexpected activity of oral fosfomycin against resistant strains of Escherichia coli in murine pyelonephritis.

Fosfomycin-tromethamine activity is well established for oral treatment of uncomplicated lower urinary tract infections but little is known about its potential efficacy in pyelonephritis. Ascending pyelonephritis was induced in mice infected with 6 strains of Escherichia coli (fosfomycin MICs: 1 g/ml to 256 g/ml). Urine pH was 4.5 before infection and 5.5-6.0 during infection. Animals were treated for 24h with fosfomycin (100 mg/kg subcutaneously every 4 hours) and CFU were enumerated in kidneys 24h after the last fosfomycin injection. Peak (20.5 g/ml at 1h) and trough (3.5 g/ml at 4h) levels in plasma were comparable to those obtained in human after an oral dose of 3 grams. Fosfomycin treatment significantly reduced bacterial loads in kidneys (3.65 log10CFU/g [min-max=1.83-7.03] and 1.88 log10CFU/g [1.78-5.74] in start-of-treatment control mice and treated mice, respectively, P < 10-6). However, this effect was not found to differ across the 6 study strains (P = 0.71) and between the 3 susceptible and the 3 resistant strains (P=0.09). Three phenomena may contribute to explain this unexpected in vivo activity: i) in mice, fosfomycin kidney/plasma concentrations ratio increased from 1 to 7.8 (95% CI, 5.2; 10.4) within 24 hours; in vitro, when pH decreased to 5: (ii) fosfomycin MICs for the 3 resistant strains (64-256 g/ml) decreased into the susceptible range (16-32 g/ml) and: iii) maximal growth rates significantly decreased for all strains and were the lowest in urine. These results suggest that local fosfomycin concentrations and physiological conditions may favour fosfomycin activity in pyelonephritis, even against resistant strains.

microbiology↗